Vacunas (English Edition)最新文献_第5页

Poliomyelitis: The paradigm of an eliminated disease. Sequelae and challenges to eradication 脊髓灰质炎：一种被消灭的疾病的范例。后遗症和根除的挑战

Vacunas (English Edition) Pub Date : 2025-10-01 Epub Date: 2025-10-07 DOI: 10.1016/j.vacune.2025.500484

José Tuells , José Antonio Hurtado-Sánchez

{"title":"Poliomyelitis: The paradigm of an eliminated disease. Sequelae and challenges to eradication","authors":"José Tuells , José Antonio Hurtado-Sánchez","doi":"10.1016/j.vacune.2025.500484","DOIUrl":"10.1016/j.vacune.2025.500484","url":null,"abstract":"<div><div>Polio represents one of the most emblematic cases in the history of public health. Its greatest impact occurred during the first half of the 20th century, with devastating epidemic outbreaks that caused half a million cases annually with tens of thousands of deaths, in addition to leaving many survivors permanently paralyzed. The scientific community responded in an exemplary manner by studying polio until they developed two effective vaccines: an inactivated vaccine (Salk, 1955) and an attenuated vaccine (Sabin, 1962). A global response was immediately organized based on international cooperation, well-defined immunization strategies, and epidemiological surveillance. The mass vaccination effort carried out since 1988 through the Global Polio Eradication Initiative (GPEI) managed to reduce cases by 99.9%. Currently, the wild polio virus only persists in Afghanistan and Pakistan, and the GPEI's “Eradication Strategy 2022–2026” has been implemented with the hope of certifying its complete eradication in the coming years. Two significant challenges remain: controlling outbreaks caused by vaccine-derived polioviruses and increasing low immunization coverage in certain regions.</div></div>","PeriodicalId":101272,"journal":{"name":"Vacunas (English Edition)","volume":"26 4","pages":"Article 500484"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145341044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges towards global measles and rubella elimination 全球消除麻疹和风疹的挑战

Vacunas (English Edition) Pub Date : 2025-10-01 Epub Date: 2025-07-30 DOI: 10.1016/j.vacune.2025.500430

Núria Torner

{"title":"Challenges towards global measles and rubella elimination","authors":"Núria Torner","doi":"10.1016/j.vacune.2025.500430","DOIUrl":"10.1016/j.vacune.2025.500430","url":null,"abstract":"<div><div>Measles and rubella are two vaccine-preventable viral diseases. Vaccination with the measles and rubella containing vaccines (MMR) has significantly reduced the incidence of these diseases, but measles remains a major cause of morbidity and mortality worldwide. Eliminating these diseases requires maintaining high levels of immunity in the population and a comprehensive approach to vaccination programs and primary health care. The WHO has established strategic plans for the elimination of measles and rubella, achieving significant progress in vaccination coverage and reducing cases and deaths. Although vaccination is a highly effective public health intervention, vaccine hesitancy has increased in recent years due to several factors, especially since the COVID-19 pandemic. Pressure from anti-vaccine movements on social media, psychological stress, mental health issues, and a lack of education among health professionals are some of the factors contributing to this hesitancy. To address this problem, which the WHO identified as one of the world's top public health challenges in 2019, a comprehensive and coordinated approach involving all sectors of society is needed to achieve the goal of global elimination.</div></div>","PeriodicalId":101272,"journal":{"name":"Vacunas (English Edition)","volume":"26 4","pages":"Article 500430"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145341045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of hepatitis B virus immunization 乙型肝炎病毒免疫的影响

Vacunas (English Edition) Pub Date : 2025-10-01 Epub Date: 2025-09-24 DOI: 10.1016/j.vacune.2025.500482

Jaime Jesús Pérez Martín , Victoria Uroz Martínez

{"title":"Impact of hepatitis B virus immunization","authors":"Jaime Jesús Pérez Martín , Victoria Uroz Martínez","doi":"10.1016/j.vacune.2025.500482","DOIUrl":"10.1016/j.vacune.2025.500482","url":null,"abstract":"<div><div>Hepatitis B virus (HBV) infection remains a global public health issue due to its potential for chronicity and severe complications such as cirrhosis and hepatocellular carcinoma. Since its introduction in the 1980s, vaccination against HBV has proven to be a highly effective tool in preventing acute infection, chronic disease, and vertical transmission. This article reviews the impact of hepatitis B vaccination globally and in Spain, based on data from epidemiological surveillance, seroprevalence studies, and cancer registries. Remarkable reductions in the incidence of chronic infection and hepatocellular carcinoma have been observed in countries that implemented the vaccine early, such as Taiwan, China, and Iran. In Spain, vaccination began in risk groups in 1982, was extended to adolescents in the 1990s, and to infants from 2002. Vaccination coverage has exceeded 93% in infants for over two decades. The incidence of acute hepatitis B has decreased significantly since 1997, and seroepidemiological studies show a marked decline in infection among individuals under 40 years old. A significant reduction in vertical transmission and hepatocellular carcinoma incidence has also been documented in Spanish men aged 35–39 years. Although systematic vaccination has had a substantial impact on the HBV disease burden, challenges remain regarding surveillance in unvaccinated or vulnerable populations, especially in the context of migration movements.</div></div>","PeriodicalId":101272,"journal":{"name":"Vacunas (English Edition)","volume":"26 4","pages":"Article 500482"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145341046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hepatitis A: Impact of vaccination 甲型肝炎：疫苗接种的影响

Vacunas (English Edition) Pub Date : 2025-10-01 Epub Date: 2025-07-29 DOI: 10.1016/j.vacune.2025.500428

Angela Domínguez , Núria Soldevila , Lluís Salleras

{"title":"Hepatitis A: Impact of vaccination","authors":"Angela Domínguez , Núria Soldevila , Lluís Salleras","doi":"10.1016/j.vacune.2025.500428","DOIUrl":"10.1016/j.vacune.2025.500428","url":null,"abstract":"<div><div>Hepatitis A has a worldwide distribution, with incidence varying according to the level of endemicity. High endemicity countries are those with a prevalence of infection in the general population greater than 50% and an annual incidence greater than 150 cases/100,000 inhabitants, while very low endemicity countries corresponds to a prevalence of infection at the age of 30 years less than 50% and an annual incidence of less than 5 cases/100,000.</div><div>Population impact of the universal vaccination strategy has been demonstrated in multiple contexts, with a decrease in the incidence of cases observed not only in those age groups that receive vaccination but also in unvaccinated population.</div><div>Although elimination targets for viral hepatitis are primarily quantified for hepatitis B and C, which cause the majority of deaths, WHO's global health strategy targets the five viruses (A, B, C, D, and E) that cause hepatitis. Interventions include ensuring high sanitation levels and water and food security, as well as vaccination against hepatitis A.</div><div>The single-dose vaccination strategy implemented in some countries has proven to be cost-effective. Currently, the biggest obstacle to universal vaccination in low-endemicity countries is its cost. It would be important to consider the indirect protective effect of vaccination to estimate the true impact of universal vaccination.</div></div>","PeriodicalId":101272,"journal":{"name":"Vacunas (English Edition)","volume":"26 4","pages":"Article 500428"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145341047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Meningococcus: Impact of meningococcal vaccination in Spain 脑膜炎球菌：在西班牙接种脑膜炎球菌疫苗的影响

Vacunas (English Edition) Pub Date : 2025-10-01 Epub Date: 2025-07-31 DOI: 10.1016/j.vacune.2025.500451

Josep Marès Bermúdez

引用次数: 0

Impact of conjugate vaccines on the evolution of invasive pneumococcal disease (IPD) in Spain 结合疫苗对西班牙侵袭性肺炎球菌病（IPD）演变的影响

Vacunas (English Edition) Pub Date : 2025-10-01 Epub Date: 2025-07-31 DOI: 10.1016/j.vacune.2025.500452

Covadonga Pérez-García , Mirella Llamosí , Inés Pareja-Cerbán , Aída Úbeda , Erick Joan Vidal-Acántara , Jose Yuste , Mirian Domenech , Julio Sempere

{"title":"Impact of conjugate vaccines on the evolution of invasive pneumococcal disease (IPD) in Spain","authors":"Covadonga Pérez-García , Mirella Llamosí , Inés Pareja-Cerbán , Aída Úbeda , Erick Joan Vidal-Acántara , Jose Yuste , Mirian Domenech , Julio Sempere","doi":"10.1016/j.vacune.2025.500452","DOIUrl":"10.1016/j.vacune.2025.500452","url":null,"abstract":"<div><div>Invasive pneumococcal disease (IPD) is a public health problem with high morbidity and mortality, especially in children and older adults. Despite pneumococcal conjugate vaccines (PCV), serotype replacement and antibiotic resistance are important challenges. This study analyses the evolution of IPD in Spain during the last 15 years, assessing the impact of vaccination in serotype distribution and antimicrobial resistance to penicillin and erythromycin. Since the introduction of PCV13, IPD cases by vaccine serotypes have decline in pediatric population. However, an increase of non-vaccine serotypes such as 8 and 24F was observed. In adults, we also found a reduction on IPD cases by vaccine serotype due to herd immunity. The COVID-19 pandemic diminished pneumococcal transmission in 2020–2021, but in 2023 we recovered pre-pandemic levels. In the last years, we have observed an increase of cases by serotype 3 in children and adults which is worrisome. From the antibiotic resistance perspective, the use of PCVs have also decline the circulation of vaccine serotypes associated with antibiotic resistance, although an increase by serotypes 11A and 24F has been observed in the last years. The use of broader vaccines and epidemiological surveillance are essential aspects necessary to improve prevention strategies.</div></div>","PeriodicalId":101272,"journal":{"name":"Vacunas (English Edition)","volume":"26 4","pages":"Article 500452"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145341049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of maternal pertussis vaccination, 2014–2023 2014-2023年孕产妇百日咳疫苗接种的影响

Vacunas (English Edition) Pub Date : 2025-10-01 Epub Date: 2025-09-25 DOI: 10.1016/j.vacune.2025.500464

Eva Borràs López

引用次数: 0

Anniversary special edition: Introduction 周年纪念特别版：引言

Vacunas (English Edition) Pub Date : 2025-10-01 Epub Date: 2025-10-08 DOI: 10.1016/j.vacune.2025.500491

Núria Torner Editora jefe, Angela Domínguez Directora científica, Lluís Salleras Director fundacional

引用次数: 0

The value of vaccines 疫苗的价值

Vacunas (English Edition) Pub Date : 2025-10-01 Epub Date: 2025-07-22 DOI: 10.1016/j.vacune.2025.500462

Magda Campins

引用次数: 0

Design of a new multi-epitope subunit vaccine to combat the EIA virus, targeting Pol, Gag, and Env proteins: In silico technique 一种新的多表位亚基疫苗的设计，以对抗EIA病毒，针对Pol， Gag和Env蛋白：在硅技术

Vacunas (English Edition) Pub Date : 2025-07-01 Epub Date: 2025-07-31 DOI: 10.1016/j.vacune.2025.500463

M. Rahiyab, I. Ul Haq, S.S. Ali, Z. Hussain, S. Ali, I. Khan, A. Iqbal

{"title":"Design of a new multi-epitope subunit vaccine to combat the EIA virus, targeting Pol, Gag, and Env proteins: In silico technique","authors":"M. Rahiyab, I. Ul Haq, S.S. Ali, Z. Hussain, S. Ali, I. Khan, A. Iqbal","doi":"10.1016/j.vacune.2025.500463","DOIUrl":"10.1016/j.vacune.2025.500463","url":null,"abstract":"<div><h3>Background</h3><div>Equine Infectious Anemia Virus (EIAV) is a lentivirus, a member of the Retroviridae, that affects horses and is distributed nearly everywhere in the world. It results in a chronic infection followed by recurrent fever episodes linked to viremia, thrombocytopenia, and symptoms of atrophy. An alternate way of preventing this disease is vaccination or immunization.</div></div><div><h3>Materials and methods</h3><div>Numerous immunoinformatics algorithms were applied to determine potential epitopes (CTL, HTL, and B-cells) from the three structural proteins (polyprotein, gag, and envelope).</div></div><div><h3>Results</h3><div>Based on the prior research, the 50S ribosomal subunit protein L7/L12 of <em>Mycobacterium tuberculosis</em> was added to the vaccine, including several linkers for connecting epitopes. After designing a multi-epitope subunit vaccine (MESV), the structure was validated by exploiting the ERRAT, Ramachandran plot, and the ProSa-web. The validated structure was docked with TLR3 and TLR8. The structure of the vaccine was submitted to GROMAX for the MD simulation. The results indicated stability and proper folding. Using a codon optimization technique, the vaccine's GC contents and CAI values were 50.84% and 0.99, respectively. The pET28a (+) vector demonstrated an appropriate expression of the vaccine. Finally, in immune simulation, TC and TH-cell populations, including high concentrations of IgG + IgM and IgG1 + IgG2 immunoglobulins, and different cytokines (e.g., IFN-g, IL-2, etc.) are consistent with natural immunity and also show quicker antigen elimination.</div></div><div><h3>Conclusion</h3><div>This new research will be helpful for upcoming experimental evaluations to validate the safety and antigenic potency of the constructed vaccine and, eventually, to treat diseases linked to the EIA virus.</div></div>","PeriodicalId":101272,"journal":{"name":"Vacunas (English Edition)","volume":"26 3","pages":"Article 500463"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144749437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0